Nemes Laszlo
- A phase 3 study of Johnson & Johnson’s (NYSE:JNJ) Darzalex (daratumumab) showed that the monoclonal antibody is effective against a type of early-stage multiple myeloma.
- Results from the Aquila trial, presented as an abstract at an American College of Hematology conference, found that the primary endpoint, progression-free survival was met. Projected 60-month PFS for those in the Darzalex arm was 63.1% compared to 40.8% for those in a control group.
- Among secondary endpoints, overall survival was 93% in the Darzalex group and 86.9% in the active monitoring group.
- Patients enrolled had high-risk smoldering multiple myeloma, a condition that can progress to active multiple myeloma. Active monitoring is the current standard of care for these patients.
- Regarding side effects, 40.4% of Darzalex-treated participants experienced Grade 3 or 4 treatment-emergent adverse events vs. 30.1% in the active monitoring group.